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Psoriasis and Cardiovascular Risk: 
Strength in Numbers, Part II
Joel M. Gelfand1,2,3, Nehal N. Mehta3,4 and Sinéad M. Langan1,2,3
The Psoralen plus Ultraviolet-A (PUVA) cohort study has been a tremendous suc-
cess in determining how a novel treatment (i.e., PUVA) affects the long-term risk of 
keratinocyte carcinoma. The ability to follow patients from the initial multicenter 
clinical trial for more than three decades has been a remarkable achievement in 
dermatoepidemiology. In this issue, Stern and Huibregtse report results from the 
PUVA follow-up study and conclude that only patients with exceptionally severe 
psoriasis have an increased overall mortality risk and that there is no significant risk 
of cardiovascular mortality associated with psoriasis. The results are in contrast to a 
large and growing body of literature that suggests patients with more severe psori-
asis have a clinically significant increased risk of mortality in general and cardiovas-
cular disease in particular. In addition, the authors found no association between 
severe psoriasis and obesity or between obesity and cardiovascular mortality, 
despite extensive literature establishing these associations. Basic principles of epi-
demiological study design may explain these discrepancies. Ultimately, however, 
randomized clinical trials will be necessary to determine whether severe psoriasis 
is in fact a “visible killer,” as four decades ago (after many years of controversy) 
hypertension was recognized to be a “silent killer.”
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What is known about psoriasis and 
cardiovascular risk?
As recently reviewed in this journal, the 
evolving evidence from the epidemio-
logical literature suggests that patients 
with psoriasis severe enough to require 
systemic medications or phototherapy 
have an increased prevalence of major 
cardiovascular (CV) risk factors and a 
clinically significant increased risk of 
major CV events such as myocardial 
infarction, stroke, and CV death that 
is independent of conventional risk 
factors (Gelfand et al., 2010). These 
epidemiological studies, combined 
with a better understanding of the 
pathophysiology of psoriasis, have led 
to the recognition that psoriasis may 
have the potential to affect more than 
skin; it is now considered a systemic 
inflammatory disorder (Davidovici et 
al., 2010; Menter et al., 2008).
Two recent studies have added to 
this previously summarized literature. 
First, Ahlehoff et al. (2010), in a nation-
wide Danish study of 34,371 people 
with mild psoriasis and 2,621 with 
severe psoriasis, demonstrated inde-
pendent risk ratios (RRs) for CV death 
of 1.14 (95% confidence interval (95% 
CI) 1.06–1.22) and 1.57 (95% CI 1.27–
1.94), respectively, with the greatest 
increase in young people (ages 18–50, 
RR 2.98, 95% CI 1.32–6.73) with 
severe disease. The authors also com-
pared CV risks in patients with severe 
psoriasis with the risks in patients with 
diabetes mellitus and found compa-
rable increases in major adverse CV 
events and CV deaths in these groups, 
demonstrating the clinical importance 
of the risk of CV disease attributable 
to psoriasis. Other recent studies have 
investigated the clinical significance of 
CV risk in patients with severe psoriasis, 
demonstrating that these patients have 
about a 6-year reduction in life expec-
tancy and that excess risk of CV death is 
the largest contributor to this premature 
mortality (Abuabara et al., 2010).
PUVa follow-up study
In contrast to all of this prior work, 
Stern and Huibregtse (2011) report that 
the risk of CV death was not increased 
compared with that in the US popula-
tion (standardized mortality ratio (SMR) 
1.02, 95% CI 0.90–1.16) and that the 
risk of CV death was slightly but not sta-
tistically significantly higher in patients 
in the highest quartile of extent of psori-
asis compared with those in the lowest 
quartile (hazard ratio (HR) adjusted for 
age and sex 1.37, 95% CI 0.97–1.94, 
multivariate HR 1.23, 95% CI 1.23, 
95% CI 0.85–1.80). Additionally, the 
authors found no increase in frequen-
cy of obesity in their cohort of severe 
psoriasis patients compared with the 
general US population and no statisti-
cally significant association of obesity 
with CV mortality, despite vast bodies 
of literature establishing these strong 
associations (Azfar and Gelfand, 2008; 
Davidovici et al., 2010; Flegal et al., 
2007; Love et al., 2010; Menter et al., 
2008; Zhang et al., 2008). Basic prin-
ciples of epidemiological study design 
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may help explain the discrepancy 
between the mortality experience in 
the Psoralen plus Ultraviolet-A (PUVA) 
follow-up study and studies of psoriasis 
patients identified using population-
based methods.
Principles of epidemiological study 
design relevant to reconciling the results
Epidemiologists attempt to design 
observational studies using methods 
that minimize bias (selection and infor-
mation), confounding, and statistical 
error (Table 1 and Figure 1). To achieve 
these goals, modern approaches 
rely on “population-based” designs 
(Figure 1). Population-based studies 
are defined as those in which the cases 
(or exposed patients in cohort stud-
ies) are a representative sample of all 
cases (or exposed patients in cohort 
studies) in a well-defined population, 
and the controls are sampled directly 
from the same source population from 
which the cases (or exposed patients 
in cohort studies) were derived (Strom, 
2005). Thus, an advantage of popu-
lation-based studies is that the com-
parison group is from the same source 
population from which the exposed 
cohort was derived, a basic require-
ment for minimizing selection bias 
(Hennekens and Buring, 1987).
Selection bias. In contrast to the other 
studies described above, the PUVA 
follow-up study was not population 
based; subjects were derived from a 
clinical trial of a novel therapeutic 
intervention (n = 1,450) conducted at 
16 leading academic dermatology cen-
ters in the United States in 1975–1976 
(Melski et al., 1977). Further, and criti-
cally, the study did not have an inter-
nal comparison group. Instead, the 
authors compared the PUVA mortality 
experience with that of the general US 
white population, calculating an SMR. 
Comparing a study population that was 
willing and able to have its health sta-
tus carefully monitored by the investi-
gators for decades with the general US 
white population introduces selection 
bias because the study subjects dif-
fer from the general white US popula-
tion in important ways that could affect 
mortality rates. Furthermore, it has 
been recognized for many years that 
patients who participate in clinical trials 
tend to be healthier than patients with 
the disease of interest who do not par-
ticipate (Britton et al., 1999; Rothwell, 
2005). Thus, it is probable that the study 
compares apples to oranges. Based 
on factors inherent to selection and 
participation, patients in the PUVA 
cohort are more likely to have different 
health-seeking behaviors, higher socio-
economic status, and access to higher-
quality medical care compared with the 
general white US population, akin to the 
“healthy worker effect” in occupational 
cohort studies; therefore, direct compar-
ison of these groups may be erroneous 
(Britton et al., 1999). Moreover, even 
when these basic criteria are met (the 
best-case scenario), SMRs have been 
shown to underestimate mortality risk 
associated with exposures compared 
with using a more appropriate internal 
control group (Card et al., 2006). Finally, 
detailed data necessary for interpreting 
mortality studies, such as prevalence of 
major risk factors for death (e.g., history 
of cancer, atherosclerosis, diabetes, and 
hyperlipidemia), are not reported.
An equally important problem with 
using general US rates is that they do not 
capture the huge variation in all-cause 
and CV mortality rates among states 
(and even within states) in the United 
States. For example, one of the study 
centers was from a state (Minnesota) 
that has the lowest CV mortality rate in 
the United States (27% lower than the 
national mean and 81% lower than the 
state with the highest CV mortality rate; 
Rosamond et al., 2008).
As a result, one cannot determine 
whether the mortality experience of the 
PUVA cohort was attributable to the 
patients’ being more health conscious, 
their having better access to medical 
care at academic medical centers, their 
having better socioeconomic status, 
etc., and/or the variations in mortality 
that exist among the states.
Information bias: measurement of out-
come. In this study, mortality experience 
in psoriasis patients was determined 
on the basis of telephone interviews 
with patients, clinicians, or patients’ 
relatives or extraction from death cer-
tificates and review by the authors if 
there was ambiguity (15% of cases). 
Death rates for the US population were 
derived from routine data sources. The 
different approaches used to ascertain 
the cause of death may introduce infor-
mation bias (Table 1 and Figure 1). If 
this error is random, then typically bias 
toward the null would result. However, 
if the error is systematic, then the direc-
tion of bias could be difficult to deter-
mine. Importantly, the authors do not 
table 1. relevant definitions
Bias Any systematic error in the design, conduct, or analysis of a study that 
results in a mistaken estimate of an exposure’s effect on the risk of disease
Selection bias Any systematic error that arises from methods to select participants for 
inclusion in a study that is differentially related to the odds of developing 
the outcome of interest
Information bias Any systematic error in measuring exposure or outcome resulting in dif-
ferential accuracy of information between groups
Confounding An observed association (or lack of one) caused by a mixing of effects 
among the exposure, the disease, and a third factor (a confounding 
variable). By definition, a confounding variable is associated with the 
exposure and, independent of that exposure, affects the risk of developing 
the disease
Statistical error, type I The effect is interpreted as significant (i.e., an association exists) when in 
fact the association is caused by chance. Type I error is determined by the 
P value. The risk of type I error increases with multiple comparisons
Statistical error, type II The effect is interpreted as not significant (i.e., there is no association), 
when in fact the association does exist. Type II error is estimated by statisti-
cal power. The actual power of the study is determined by the range of the 
95% confidence interval
Confidence interval This represents the range within which the true magnitude of the effect in 
a population lies with a certain degree of confidence. With a 95% confi-
dence interval, this means that if the study were repeated 100 times, 95% 
of the observations would occur within the confidence interval
From Hennekens and Buring, 1987.
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describe any deaths related to accidents 
or Alzheimer’s disease (the fifth and 
sixth most common causes of deaths 
in the United States; Xu, 2010). Based 
on routine statistics, about 31 deaths 
would have been expected from acci-
dents and 19 deaths from Alzheimer’s 
disease. The absence of these major 
causes of death in this study could be 
attributable to either the method of 
data extraction or the fact that this is 
a specialized population with mortal-
ity experience different from that of the 
general US population.
Information bias: measurement of 
exposure. Stern and Huibregtse (2011) 
attempt to address the fundamental 
limitations of their primary analy-
sis (selection bias and the lack of an 
internal comparator) by examining the 
risk of mortality among patients with 
psoriasis of varying severity. Severity 
was assessed at one point in time and 
divided into quartiles based on the 
body surface area (BSA) involved. 
The lowest quartile included patients 
meeting the definition of moderate to 
severe psoriasis, and thus a compari-
son to an internal group of mild pso-
riasis patients was not conducted (Kurd 
and Gelfand, 2009). Psoriasis severity 
and exposure to the majority of covari-
ates were based on assessment at the 
study outset three decades prior to 
study completion. Therefore, the find-
ings represent associations between 
psoriasis extent at one point in time 
and mortality decades later. Changes 
in covariates with time were consid-
ered for smoking, PUVA, and metho-
trexate dose; however, these were 
categorized as “more than the mean 
exposure” that year or not, rather than 
either as a binary “yes/no” variable or 
a time-varying covariate. Given the age 
distribution of the study population in 
1976 (5–85 years), significant changes 
are also likely to have occurred in pso-
riasis severity as well as in the mea-
sured covariates (blood pressure, body 
mass index) and unmeasured covari-
ates (e.g., lipids and glucose) (Nijsten 
et al., 2007). Additionally, several of 
the exposures included as confound-
ers in this analysis (e.g., uric acid level) 
are potentially in the causal pathway 
between psoriasis and CV disease; 
therefore, their inclusion in multivari-
able analyses could erroneously mask 
important associations (Feig et al., 
2008). Given these analytic issues, the 
observation of excess mortality based 
on a single measurement of affected 
BSA more than 30 years earlier among 
a cohort of patients with severe psoria-
sis is remarkable. To put this finding in 
perspective, being in the top quartile of 
psoriasis severity in the PUVA cohort 
was associated with mortality (HR 
1.55, 95% CI 1.23–1.93) to a greater 
extent than being in the top 15th per-
centile for obesity (HR 1.27, 95% CI 
1.03–1.57).
Statistical error. One of the study 
objectives was to compare mortality 
experience between groups of patients 
with the most (n = 349) and least 
(n = 326) extensive psoriasis, bearing 
in mind that all participants had severe 
disease. The authors found an HR of 
1.37 (95% CI 0.97–1.94) for CV mortal-
ity in the most severe group. The wide 
confidence interval demonstrates a lack 
of statistical power to detect a clinically 
meaningful higher CV mortality (type II 
error). For example, in their multivari-
able models the top quartile of psoria-
sis severity was associated with a simi-
lar degree of risk as well-established 
risk factors such as smoking (HR 1.35, 
95% CI 1.03–1.77). Moreover, the esti-
mate of CV mortality in the most severe 
group is statistically similar (based 
on 95% CI) to that observed in prior 
population-based studies assessing 
major CV events (Ahlehoff et al., 2010; 
Brauchli et al., 2009; Gelfand et al., 
2006, 2009; Kaye et al., 2008; Mehta et 
al., 2009; Xiao et al., 2009).
What are the conclusions  
and future directions?
As indicated by Stern and Huibregtse 
(2011) and consensus statements from 
the editors of the American Journal of 
Cardiology and the Medical Board 
of the National Psoriasis Foundation, 
clinicians should screen patients with 
severe psoriasis for CV risk factors and 
be sure that patients with risk factors 
receive appropriate counseling and 
treatment (Friedewald et al., 2008; 
Kimball et al., 2008). The potential ben-
efit of setting more aggressive cardio-
protective treatment goals for patients 
with severe psoriasis, as has been 
recommended for patients with other 
inflammatory diseases having similar 
evidence of excess CV risk (e.g., rheu-
matoid arthritis), should be explored 
further (Peters et al., 2010). To investi-
gate these issues more fully, we have 
established a population-based cohort 
study of more than 4,000 patients 
with varying levels of psoriasis sever-
ity who are being followed prospec-
tively for major CV events (Seminara 
et al., 2010). Furthermore, based on 
the evolving understanding of the sys-
temic nature of psoriasis, a critical goal 
is to move interventional trials in pso-
riasis beyond short-term assessments 
of changes in skin disease and quality 
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Figure 1. Unified concept of analytical epidemiology studies, highlighting the major sources of error.
commentary
1010 Journal of Investigative Dermatology (2011), Volume 131 
of the impact of treatment on the risk 
of developing CV, metabolic, and 
joint disease (i.e., psoriatic arthritis). 
Interestingly, the PUVA cohort found 
a 26% reduction in CV mortality (HR 
0.74, 96% CI 0.56–0.97) in those 
receiving more than the mean num-
ber of PUVA treatments, suggesting 
that more aggressive treatment of pso-
riasis might improve health outcomes. 
Ultimately, randomized interventional 
trials will be necessary to determine 
whether severe psoriasis is in fact a 
“visible killer,” as (after many years of 
controversy) randomized trials starting 
in the 1960s demonstrated hyperten-
sion to be a “silent killer” (Freis, 1990).
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